{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anti-Dyskinesia+Agents",
    "query": {
      "condition": "Anti-Dyskinesia Agents"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T16:00:25.060Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02634684",
      "title": "Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Dextroamphetamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 82,
      "start_date": "2014-07-01",
      "completion_date": "2020-08",
      "has_results": true,
      "last_update_posted_date": "2021-08-17",
      "last_synced_at": "2026-06-10T16:00:25.060Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02634684"
    },
    {
      "nct_id": "NCT01491932",
      "title": "Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyskinesias",
        "Parkinson Disease",
        "Movement Disorders",
        "Parkinsonian Disorders",
        "Anti-Dyskinesia Agents"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 129,
      "start_date": "2012-03",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-06-10T16:00:25.060Z",
      "location_count": 3,
      "location_summary": "Englewood, Colorado • Kansas City, Kansas • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01491932"
    },
    {
      "nct_id": "NCT03250117",
      "title": "Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Ropinirole oral product",
          "type": "DRUG"
        },
        {
          "name": "Ropinirole Implant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Titan Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 6,
      "start_date": "2017-10-10",
      "completion_date": "2018-05-22",
      "has_results": true,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-06-10T16:00:25.060Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Farmington Hills, Michigan • Kirkland, Washington",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Kirkland",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03250117"
    },
    {
      "nct_id": "NCT05021991",
      "title": "A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Essential Tremor"
      ],
      "interventions": [
        {
          "name": "100 mg PRAX-944",
          "type": "DRUG"
        },
        {
          "name": "60 mg PRAX-944",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Flexibly dosed 20 mg to 100 mg PRAX-944",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Praxis Precision Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2021-10-14",
      "completion_date": "2024-02-29",
      "has_results": false,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-06-10T16:00:25.060Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05021991"
    },
    {
      "nct_id": "NCT01385592",
      "title": "Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyskinesias",
        "Parkinson Disease",
        "Movement Disorders",
        "Parkinsonian Disorders"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 78,
      "start_date": "2011-11",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-06-10T16:00:25.060Z",
      "location_count": 2,
      "location_summary": "Sunnyvale, California • Englewood, Colorado",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01385592"
    },
    {
      "nct_id": "NCT05021978",
      "title": "A Clinical Trial of PRAX-944 in Participants With Essential Tremor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Essential Tremor"
      ],
      "interventions": [
        {
          "name": "Part A: 20 and 40 mg PRAX-944",
          "type": "DRUG"
        },
        {
          "name": "Part B: 120 mg PRAX-944",
          "type": "DRUG"
        },
        {
          "name": "Part B: 120 mg PRAX-944 and Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Praxis Precision Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2020-03-03",
      "completion_date": "2022-03-24",
      "has_results": true,
      "last_update_posted_date": "2024-03-01",
      "last_synced_at": "2026-06-10T16:00:25.060Z",
      "location_count": 2,
      "location_summary": "Port Charlotte, Florida • Spokane, Washington",
      "locations": [
        {
          "city": "Port Charlotte",
          "state": "Florida"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05021978"
    },
    {
      "nct_id": "NCT00000179",
      "title": "Agitation in Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Trazodone",
          "type": "DRUG"
        },
        {
          "name": "Haloperidol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-06-10T16:00:25.060Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • San Diego, California • Miami, Florida + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000179"
    },
    {
      "nct_id": "NCT06087276",
      "title": "Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Essential Tremor"
      ],
      "interventions": [
        {
          "name": "60 mg ulixacaltamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Praxis Precision Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2023-11-02",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-06-10T16:00:25.060Z",
      "location_count": 1,
      "location_summary": "Morgantown, West Virginia",
      "locations": [
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06087276"
    },
    {
      "nct_id": "NCT01491529",
      "title": "Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyskinesias",
        "Parkinson Disease",
        "Movement Disorders",
        "Parkinsonian Disorders",
        "Anti-Dyskinesia Agents"
      ],
      "interventions": [
        {
          "name": "AFQ056",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 154,
      "start_date": "2012-04",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-06-10T16:00:25.060Z",
      "location_count": 5,
      "location_summary": "Sunnyvale, California • Englewood, Colorado • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01491529"
    }
  ]
}